VITORA: Clinical Study to Evaluate the Effect of KB109 on the Gut Microbiome in Subjects Whose Gastrointestinal Tracts Are Colonized With Multiple Drug-resistant Organisms (VITORA)
A Randomized, Open-Label, Prospective, Parallel Group, 2-Part Clinical Food Study to Assess the Safety, Tolerability, and Effect of KB109 on the Gut Microbiome in Subjects Whose Gastrointesinal Tracts Are Colonized With Multiple Drug-resistant Organisms
Sponsor: Kaleido Biosciences
Terminated
COVID-19 pandemic
Other terminated trials from Kaleido Biosciences
Listed as NCT03944369, this NA trial focuses on Vancomycin-Resistant Enterococcus, Extended-Spectrum Beta Lactamase-Producing Enterobacteriaceae, or Carbapenem-Resistant Enterobacteriaceae Colonized Subjects and remains terminated or withdrawn. Sponsored by Kaleido Biosciences, it has been updated 11 times since 2019, reflecting substantial change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.
Status Flow
Change History
11 versions recorded-
Sep 2024 — Present [monthly]
Terminated NA
-
Jul 2024 — Sep 2024 [monthly]
Terminated NA
-
Feb 2021 — Jul 2024 [monthly]
Terminated NA
Status: Recruiting → Terminated
-
Jan 2021 — Feb 2021 [monthly]
Recruiting NA
-
Apr 2020 — Jan 2021 [monthly]
Recruiting NA
▶ Show 6 earlier versions
-
Dec 2019 — Apr 2020 [monthly]
Recruiting NA
-
Nov 2019 — Dec 2019 [monthly]
Recruiting NA
-
Oct 2019 — Nov 2019 [monthly]
Recruiting NA
-
Sep 2019 — Oct 2019 [monthly]
Recruiting NA
-
Jul 2019 — Sep 2019 [monthly]
Recruiting NA
Status: Not Yet Recruiting → Recruiting
-
Jun 2019 — Jul 2019 [monthly]
Not Yet Recruiting NA
First recorded
Eligibility Summary
No eligibility information available.
Contact Information
- Kaleido Biosciences
For direct contact, visit the study record on ClinicalTrials.gov .